RF
RFL
Rafael Holdings, Inc.
$1.33
-2.92%
$71.3M
No data for this timeframe.
Vol
Market Cap$71.3M
Cap SizeMicro Cap
Inst. Holders5 funds
Inst. Value$2.0M
Inst. Activity0 buys / 2 sells
SEC Reports1
Press Releases1
Recent Activity
Apr 22, 2026
SEC
Rafael Holdings announced an exclusive patent license from MIT covering the use of cyclodextrins in Alzheimer's patients
8-K — Impact 4/10
Apr 22, 2026
other
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Acti
Mar 21, 2026
Insider
Polinsky David sold 2,318 shares
Chief Financial Officer @ $1.28 ($3.0K)
Mar 13, 2026
Insider
JONAS HOWARD S sold 9,826 shares
Exec Chairman, CEO & President @ $1.50 ($14.8K)
Jan 28, 2026
Insider
Sieger Markus sold 29,528 shares
Director @ $1.27 ($37.5K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
56,027 shares ($66.1K)
Inst.
BANK OF AMERICA CORP — NEAR_EXIT
1,175 shares ($1.4K)
Mar 16, 2026
Press
Rafael Holdings reported Q2 FY2026 financial results with a net loss of $6.4 million, wider than the prior year's $4.6 m
Impact 6/10
Latest Reports
NEUTRAL
8-K
4/10
Rafael Holdings announced an exclusive patent license from MIT covering the use of cyclodextrins in Alzheimer's patients
Apr 22, 2026
MIXED
Press
6/10
Rafael Holdings reported Q2 FY2026 financial results with a net loss of $6.4 million, wider than the prior year's $4.6 m
Mar 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.8M | ADD |
| WELLS FARGO & COMPANY/MN | $123.3K | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $66.1K | TRIM |
| MORGAN STANLEY | $11.6K | TRIM |
| BANK OF AMERICA CORP | $1.4K | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 21, 2026 | Polinsky David | F | $3.0K |
| Mar 13, 2026 | JONAS HOWARD | F | $14.8K |
| Jan 28, 2026 | Sieger Markus | A | $37.5K |
5 institutional holders with $2.0M total value (1,664,777 shares) as of 2025-Q4. Top holders: VANGUARD, WELLS, RENAISSANCE. Net selling activity: 2 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,493,277 | $1.8M | 89.7% | ADD +25.8% |
| 2 | WELLS FARGO & COMPANY/MN | 104,490 | $123.3K | 6.3% | DOUBLED +340.2% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 56,027 | $66.1K | 3.4% | TRIM -26.7% |
| 4 | MORGAN STANLEY | 9,808 | $11.6K | 0.6% | TRIM -37.3% |
| 5 | BANK OF AMERICA CORP /DE/ | 1,175 | $1.4K | 0.1% | NEAR_EXIT -80.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 76,431 | 56,027 | -26.7% | $66.1K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 6,166 | 1,175 | -80.9% | $1.4K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 23,485 | 103,392 | +340.2% | $140.6K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 29,831 | 76,431 | +156.2% | $103.9K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 16,001 | 10,038 | -37.3% | $13.7K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,537 | 6,166 | +301.2% | $8.4K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 1,003,341 | 1,261,702 | +25.8% | $2.2M | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 6,284 | 16,001 | +154.6% | $27.7K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 845 | 1,537 | +81.9% | $2.7K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 23,112 | 0 | -100.0% | $0.00 | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 702,160 | 1,003,341 | +42.9% | $1.9M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 72,591 | 28,331 | -61.0% | $53.0K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,866 | 23,482 | +1158.4% | $43.9K | 2025-Q1 |
| UBS Group AG | DOUBLED | 1,130 | 2,537 | +124.5% | $4.7K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 766 | 1,866 | +143.6% | $3.1K | 2024-Q4 |
3 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 21, 2026 | Polinsky David | Chief Financial Officer | F | 2,318 | $1.28 | $3.0K |
| Mar 13, 2026 | JONAS HOWARD S | Exec Chairman, CEO & President | F | 9,826 | $1.50 | $14.8K |
| Jan 28, 2026 | Sieger Markus | Director | A | 29,528 | $1.27 | $37.5K |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 22, 2026
other
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatmen
Mar 18, 2026
earnings_calendar
RFL Q2 2026 Earnings Scheduled — 2026-03-18
Mar 16, 2026
earnings
Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
<p align="justify">NEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the s
Mar 11, 2026
earnings_calendar
RFL Q2 2026 Earnings Scheduled — 2026-03-11